Peptides Vietnam LogoPeptides Vietnam
EN/VI
Molecule MechanicsNov 2026

What Is Wegovy? How the Semaglutide Shot Works

What is Wegovy? It is a prescription medicine from Novo Nordisk whose active ingredient, semaglutide, is a man-made form of GLP-1, a hormone your gut releases after meals. Natural GLP-1 is broken down extremely fast. Semaglutide was changed so it lasts for days, and its shot is approved in the US for three uses: weight, heart risk and a liver disease.

Below, we follow the molecule from the gut hormone it copies to the three small changes that keep it around, then look at what the big trials measured and what the current label, re-read on 20 November 2026, approves and warns about.

On this page

What is Wegovy, in one table?

Six lines cover the basics. Each one is unpacked further down the page.

Wegovy at a glance, from the US label and FDA records, checked November 2026.
PointWegovy
What it isA prescription medicine from Novo Nordisk, approved in the US
Active ingredientSemaglutide, a lab-made GLP-1 analog with a yeast-made backbone
What it copiesGLP-1, a gut hormone released after meals
Why it lastsIt grips albumin, a blood protein; half of it takes about a week to clear
Approved uses of the shotHeart risk in some adults, weight reduction and maintenance, and the liver disease MASH
Label checkedVersion 19, published 30 June 2026, read on DailyMed 20 November 2026

Sources: Wegovy prescribing information, DailyMed, version 19; DailyMed label list for Wegovy; Drugs@FDA record, NDA 215256

Which gut hormone does Wegovy copy?

GLP-1, short for glucagon-like peptide 1. After you eat, L-cells in the lining of your gut release this small hormone, a chain of 30 amino acids. It acts as one of the body's own signals about food and appetite.

The catch is speed. An enzyme called DPP-4 chops natural GLP-1 apart extremely fast, even before the hormone has left the gut. Semaglutide was designed to resist that breakdown.

Sources: Holst 2007, GLP-1 physiology review (PMID 17928588); Wegovy prescribing information, DailyMed, version 19

How was semaglutide built to last?

With three changes to the natural chain. Yeast makes the peptide backbone, and it matches 94 percent of human GLP-1, close enough to switch on the same receptor. Then Novo Nordisk chemists made their edits. They put an unusual building block called Aib at position 8, a change the label says shields it from DPP-4, so the enzyme cannot chop it easily. They swapped position 34 for arginine. And at position 26 they hung a fatty acid chain off a lysine.

That fatty chain is the big one. It makes semaglutide stick to albumin, a protein that floats in your blood, and the label names albumin binding as the main reason the drug lasts. Picture a rowboat tied to a ferry: the current cannot carry it off.

The result is a half-life of about one week in people, so half of what is in the blood clears in that time. The label adds that semaglutide stays in circulation for roughly 5 to 7 weeks after it is stopped. How these same edits compare with an older GLP-1 molecule is shown on our Saxenda vs Wegovy page.

Sources: Wegovy prescribing information, DailyMed, version 19; Lau 2015, discovery of semaglutide (PMID 26308095); Holst 2007, GLP-1 physiology review (PMID 17928588)

Does Wegovy work on the stomach or the brain?

The label names both. It says semaglutide delays gastric emptying, so a meal moves out of the stomach more slowly. It also says GLP-1 helps regulate appetite and calorie intake, and that its receptor sits in several brain areas involved in appetite.

How does a large molecule reach the brain? In rodent studies, semaglutide reached the brainstem, the septal nucleus and the hypothalamus without crossing the blood-brain barrier. It got in through a few spots where that barrier is thin, called circumventricular organs, and through sites next to the brain's fluid spaces. Think of fans entering a stadium through the open gates rather than climbing the wall. That is animal data.

A human trial weighed the two ideas. In a 20-week study of 72 adults with obesity, people on semaglutide ate 35 percent less at a lunch with no limit on food than people on placebo, and they reported less hunger and more fullness. Yet on an indirect test at week 20, the trial found no evidence that stomach emptying was slower once body weight was taken into account.

So in that trial, appetite seemed to carry more of the effect than a slower stomach. The trial did not test early weeks against late weeks, so whether stomach slowing fades over time is still an open question. The label adds that more of the lost weight is fat than lean mass, though some lean mass goes too.

Sources: Wegovy prescribing information, DailyMed, version 19; Gabery 2020, semaglutide in the rodent brain (PMID 32213703); Friedrichsen 2021, appetite trial (PMID 33269530)

Is semaglutide a brand new molecule?

No. Semaglutide had its first US approval in 2017, years before Wegovy. Its designers set out to make a longer lasting GLP-1 analog than an earlier drug, by raising its grip on albumin and making it fully resistant to breakdown. When Wegovy arrived on 4 June 2021, Drugs@FDA filed it as a new use for a molecule that was already approved.

The FDA noted it was the first new option since 2014 for long-term weight care in adults with general obesity or overweight. Each use since then was added as its own approval, which is why the label has grown.

Wegovy approval timeline, from Drugs@FDA records, FDA releases and the label.
DateWhat happened
2017Semaglutide gets its first US approval. The Wegovy label still says "Initial U.S. Approval: 2017".
4 June 2021Wegovy is approved for chronic weight management, filed as a new use of an already approved molecule.
8 March 2024A heart use is added for adults with heart disease who also carry obesity or overweight, to lower their risk of major heart events.
15 August 2025The liver use for MASH is added, under accelerated approval.
22 December 2025Wegovy tablets are approved under a separate application. They share the label but are not covered on this page.
30 June 2026Current label, version 19. We re-read it on 20 November 2026.

The tablets are a story of their own, told on our oral semaglutide page.

Sources: Wegovy prescribing information, DailyMed, version 19; Drugs@FDA record, NDA 215256; FDA news release, 4 June 2021 (archived copy); FDA news release, 8 March 2024; FDA news, MASH approval, 15 August 2025; Lau 2015, discovery of semaglutide (PMID 26308095)

What did the STEP weight trials find?

STEP 1 enrolled 1,961 adults with obesity, or overweight plus a weight related condition, and no diabetes. They were assigned two to one to semaglutide or placebo, a dummy comparison treatment, for 68 weeks, and both groups got lifestyle support. On average the semaglutide group's weight fell 14.9 percent, against 2.4 percent on placebo. About half of them, 50.5 percent, lost 15 percent or more, compared with 4.9 percent on placebo.

STEP 4 asked what happens when it stops. Everyone took semaglutide for a 20-week run-in. Then some carried on and some were switched to placebo. Over the next 48 weeks, the first group lost another 7.9 percent while the switched group regained 6.9 percent.

These are group averages, not a forecast for any one person. The molecule's wider research record, beyond these two trials, is collected in our semaglutide profile.

Sources: STEP 1, NEJM 2021 (PMID 33567185); STEP 4, JAMA 2021 (PMID 33755728)

What did the SELECT heart trial show?

SELECT was the largest trial on this page. It followed 17,604 adults aged 45 or older with existing heart or blood vessel disease, a BMI of 27 or more, and no diabetes, for an average of 39.8 months.

A heart attack, stroke or cardiovascular death happened to 6.5 percent of the semaglutide group and 8.0 percent of the placebo group. That is a 20 percent lower relative risk between the groups, or 1.5 percentage points in absolute terms. It describes groups, not anyone's personal odds.

The label is careful about the limits. Cardiovascular death on its own was not confirmed to be lower, and the exact way semaglutide lowers heart risk has not been established. This trial is what earned the March 2024 heart use.

Sources: SELECT, NEJM 2023 (PMID 37952131); Wegovy prescribing information, DailyMed, version 19; FDA news release, 8 March 2024

What is Wegovy approved for?

Three uses for the shot, on the label we read on 20 November 2026. Each one assumes fewer calories and more exercise alongside the medicine, not in place of them.

The three approved uses of the Wegovy shot, label version 19.
UseWho it coversSinceWhat the label says
Heart riskAdults with established heart or blood vessel disease and either obesity or overweightMarch 2024Approved to reduce the risk of major heart events: cardiovascular death, heart attack or stroke
WeightAdults and children 12 and older with obesity, or adults with overweight plus a weight related conditionJune 2021 (teen date not confirmed)Bring excess weight down and hold the loss over the long run
Liver (MASH)Adults with MASH and moderate to advanced scarring (F2 to F3), without cirrhosisAugust 2025Accelerated approval; keeping it may depend on a confirmatory trial

MASH stands for metabolic dysfunction-associated steatohepatitis, a serious fatty liver disease. That use came under accelerated approval after a breakthrough therapy designation, so keeping it may depend on a trial that confirms the benefit.

The label also advises against pairing Wegovy with any other semaglutide product or a different GLP-1 receptor agonist. The same molecule carries a different set of approvals under another brand name, laid out on our page asking is Wegovy the same as Ozempic.

Sources: Wegovy prescribing information, DailyMed, version 19; FDA news, MASH approval, 15 August 2025; Drugs@FDA record, NDA 215256

What does the Wegovy label warn about?

The boxed warning comes from rodents. In rodent studies, semaglutide caused thyroid C-cell tumors, and it is unknown whether it does so in humans. Because of that, the label rules it out when a person or their family has a record of medullary thyroid carcinoma, and in anyone with MEN 2 (multiple endocrine neoplasia syndrome type 2). It is also ruled out after a serious allergic reaction to semaglutide or its ingredients.

The most common reactions are gut related, led by nausea, diarrhea, vomiting, constipation and belly pain, and the list goes beyond the gut. The warnings section covers pancreatitis, gallbladder disease, allergic reactions, kidney injury when fluids run low, serious gut reactions and aspiration during anesthesia, among others. Our episode page on Wegovy side effects goes through them one by one, and Wegovy ingredients covers what else is in the pen.

Sources: Wegovy prescribing information, DailyMed, version 19

What do the label and trials leave open?

Reading the label next to the trial papers, we found five places where the record is less settled than a quick summary suggests.

  • Stomach versus appetite. The label says semaglutide slows stomach emptying. The 20-week appetite trial found no evidence of that at week 20. Both can be true if the stomach effect matters most early on, but no trial we found tested that.
  • How the heart benefit works. The label says the mechanism has not been established, and cardiovascular death on its own was not confirmed to fall.
  • Absolute versus relative. A 20 percent relative drop in SELECT works out to 1.5 percentage points: about 15 fewer heart attacks, strokes or cardiovascular deaths per 1,000 people, over an average follow-up of about 3.3 years in that trial group. Both numbers describe the same result.
  • The liver use is provisional. It stands on accelerated approval, which can depend on a trial that confirms the benefit.
  • One funder. STEP 1, STEP 4, SELECT, the appetite trial, the rodent brain study and the design paper were all funded by Novo Nordisk or written by its staff.

We also checked dates ourselves. Drugs@FDA lists a December 2022 efficacy update to the Wegovy application, but the record does not say which use it covers, so we give no date for the teen approval.

Sources: Wegovy prescribing information, DailyMed, version 19; Friedrichsen 2021, appetite trial (PMID 33269530); SELECT, NEJM 2023 (PMID 37952131); Drugs@FDA record, NDA 215256; STEP 1, NEJM 2021 (PMID 33567185); STEP 4, JAMA 2021 (PMID 33755728); Gabery 2020, semaglutide in the rodent brain (PMID 32213703); Lau 2015, discovery of semaglutide (PMID 26308095)

What else do people ask about Wegovy?

What is Wegovy used for?+

Its shot has three US uses, each paired with eating fewer calories and moving more. One lowers the risk of major heart events in adults who have heart disease plus obesity or overweight. One brings excess weight down and holds it there, in adults and children 12 and up with obesity, or adults with overweight plus a weight related condition. The third is for adults whose MASH, a fatty liver disease, has caused moderate to advanced scarring.

Is Wegovy the same thing as semaglutide?+

Not quite. Wegovy is a brand name, and semaglutide is the active ingredient inside it. How Wegovy relates to Ozempic is covered on our page asking whether the two are the same.

Is Wegovy a peptide?+

Its active ingredient is. The label calls semaglutide a GLP-1 analog and says yeast fermentation produces its peptide backbone, which is then changed in three places by chemists.

How long does Wegovy stay in the body?+

The label gives semaglutide an elimination half-life of about one week, so traces remain in circulation 5 to 7 weeks after the last use. Natural GLP-1, by contrast, is broken down extremely fast.

Does Wegovy work on the stomach or the brain?+

Both are named on the label: it delays stomach emptying, and GLP-1 receptors sit in brain areas tied to appetite. In one 20-week human trial, people ate 35% less at a free lunch, but the trial found no evidence of a slower stomach at week 20. So in that trial, appetite looked like the bigger factor.

Does weight lost on Wegovy come from fat or muscle?+

Both. The label says semaglutide lowers body weight with more fat mass lost than lean mass. Lean mass is still lost, just less of it.

Is Wegovy a pill or a shot?+

Both now exist. This page covers the shot. Wegovy tablets were approved on 22 December 2025 under their own application, and our oral semaglutide page explains how a peptide gets through the stomach.

Who makes Wegovy?+

Novo Nordisk. Its scientists also designed semaglutide, and every trial named on this page was funded or written by the company.

Sources: Wegovy prescribing information, DailyMed, version 19; Drugs@FDA record, NDA 215256; Friedrichsen 2021, appetite trial (PMID 33269530); Lau 2015, discovery of semaglutide (PMID 26308095)

So what is Wegovy, in short?

The takeaway: Wegovy is semaglutide, a sturdier version of your own GLP-1 that holds on to albumin, seems to cut eating mainly through appetite, and is approved for weight, for heart risk in some adults, and for a liver disease.

Each Molecule Mechanics episode animates one molecule and lists its sources under the video. For this page we leaned on the Wegovy label, Drugs@FDA, FDA releases and the trial abstracts, all as of 20 November 2026. Every trial named here was funded by Novo Nordisk or written by its staff. For a molecule that targets two receptors instead of one, see how tirzepatide works.

Spot a mistake? Our corrections policy shows how to report it, and our medical review policy sets out how status is checked.

Sources: Wegovy prescribing information, DailyMed, version 19; DailyMed label list for Wegovy

This page explains how a medicine works and gives no advice. Its facts come from the FDA label, FDA records and peer-reviewed trials, cited after each section. It does not suggest using anything, so take any health question to a licensed clinician.

Sources

  1. 1.Wegovy prescribing information and Medication Guide, Novo Nordisk, DailyMed SPL version 19 (published 30 June 2026), read 19 and 20 November 2026: the three uses of the shot, each with a reduced calorie diet and more physical activity; the MASH use is an accelerated approval that may depend on a confirmatory trial; initial US approval 2017; semaglutide is a GLP-1 analog with 94% sequence homology to human GLP-1, its backbone made by yeast fermentation; modified at position 8 against DPP-4; albumin binding is the main reason it lasts; elimination half-life about 1 week, present in the blood about 5 to 7 weeks after stopping; GLP-1 receptors in brain areas that regulate appetite; animal studies show it reached brain regions that regulate food intake; delays gastric emptying; more fat mass than lean mass lost; not recommended with other semaglutide products or other GLP-1 receptor agonists; the CV death limit and unknown mechanism in SELECT; boxed warning from rodent thyroid C-cell tumors; contraindications; most common reactions and warnings. The label covers the shot and the tablets in one document.
  2. 2.DailyMed SPL list for Wegovy, read 20 November 2026: the Novo Nordisk label is version 19, published 30 June 2026.
  3. 3.Drugs@FDA (openFDA) record for NDA 215256, read 19 November 2026: original application approved 4 June 2021 as a new indication submitted as a distinct application; efficacy supplements approved 8 March 2024 and 15 August 2025; the shot products are marked Prescription. The tablets sit under a separate application, NDA 218316, approved 22 December 2025.
  4. 4.FDA news release, 4 June 2021, archived by the Wayback Machine (the live page now returns 404): FDA approved Wegovy for chronic weight management and said no drug for that purpose in adults with general obesity or overweight had been approved since 2014.
  5. 5.FDA news release, 8 March 2024: Wegovy approved to lower the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight; FDA called it the first weight loss medication also approved to help prevent these events.
  6. 6.FDA news, 15 August 2025: Wegovy approved for MASH with moderate to advanced liver scarring, under the accelerated approval pathway after a breakthrough therapy designation.
  7. 7.Holst JJ, The physiology of glucagon-like peptide 1, Physiological Reviews 2007, PMID 17928588: GLP-1 is a 30 amino acid hormone from intestinal L-cells, released after meals, and broken down extremely fast by DPP-4, even before it leaves the gut.
  8. 8.Lau J and colleagues, J Med Chem 2015, PMID 26308095: semaglutide has two amino acid swaps versus human GLP-1 (Aib at 8, Arg at 34) and a chemical attachment at lysine 26; designed for stronger albumin grip and full stability against breakdown, a step on from an earlier GLP-1 drug. Authors are Novo Nordisk scientists.
  9. 9.Gabery S and colleagues, JCI Insight 2020, PMID 32213703, rodent study: semaglutide reached the brainstem, septal nucleus and hypothalamus without crossing the blood-brain barrier, through circumventricular organs and sites next to the ventricles. Most authors are Novo Nordisk employees.
  10. 10.Friedrichsen M and colleagues, 2021, PMID 33269530: 20-week double-blind trial in 72 adults with obesity; energy intake at a free-choice lunch was 35% lower with semaglutide than placebo, with less hunger and more fullness; no evidence of delayed gastric emptying at week 20 on an indirect test. Novo Nordisk sponsored.
  11. 11.Wilding JPH and colleagues, STEP 1, NEJM 2021, PMID 33567185: 1,961 adults with obesity or overweight and no diabetes, 68 weeks, 2 to 1 to semaglutide or placebo with lifestyle support; mean weight change minus 14.9% vs minus 2.4%; 50.5% vs 4.9% lost 15% or more. Novo Nordisk funded.
  12. 12.Rubino D and colleagues, STEP 4, JAMA 2021, PMID 33755728: after a 20-week run-in on semaglutide, those who stayed on it changed weight by minus 7.9% while those switched to placebo regained 6.9% over the next 48 weeks. Novo Nordisk funded.
  13. 13.Lincoff AM and colleagues, SELECT, NEJM 2023, PMID 37952131: 17,604 adults aged 45 or older with cardiovascular disease, BMI 27 or more and no diabetes, mean follow-up 39.8 months; heart attack, stroke or cardiovascular death in 6.5% vs 8.0% (hazard ratio 0.80). Novo Nordisk funded.